# Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

> **NCT03382834** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 31 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Vorinostat
- **DRUG:** Antiretroviral drugs

## Key facts

- **NCT ID:** NCT03382834
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2018-12-04
- **Final completion:** 2023-07-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382834, "Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03382834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*